Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: Possible signs of reparative mechanisms

Respiratory Medicine

Volumn 90, Issue 9, 1996, Pages 523-529

  Skold C M ^a   Blaschke, E ^a   Eklund, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FIBRONECTIN; HYALURONIC ACID; TOBACCO SMOKE;

ADULT; ARTICLE; CAPILLARY PERMEABILITY; CONTROLLED STUDY; EOSINOPHIL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INFLAMMATION; LUNG CAPILLARY; LUNG INTERSTITIUM; LUNG LAVAGE; LYMPHOCYTE; MACROPHAGE; MALE; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL; SMOKING CESSATION; TIME;

EID: 0029849985     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90144-4     Document Type: Article

References (38)

1. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax 1987; 42: 241-249.
2. Sköld CM, Eklund A, Halldén G, Hed J. Autofluorescence in human alveolar macrophages from smokers: relation to cell surface markers and phagocytosis. Exp Lung Res 1989; 15: 823-835.
3. Cherniack RM. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990; 141: S169-S202.
4. Pozzi E, De Rose V, Rennard SI, Fabbri LM. Guidelines and recommendations for the clinical use of bronchoalveolar lavage in chronic bronchitis and emphysema. In: Klech H, Hutter C, Costabel U, eds. Clinical Guidelines and Indicators for Bronchoalveolar Lavage (BAL). Eur Respir Rev 1992; 2: 121-124.
5. Rennard SI, Crystal RG. Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease. J Clin Invest 1981; 69: 113-122.
6. Hällgren R, Eklund A, Engström-Laurent A, Schmekel B. Hyaluronate in bronchoalveolar lavage fluid: a new marker in sarcoidosis reflecting pulmonary disease. BMJ 1985; 290: 1778-1781.
7. O'Connor C, Ward K, van Breda A, Mcllgorm A, FitzGerald MX. Type 3 procollagen peptide in bronchoalveolar lavage fluid. Poor indicator of course and prognosis in sarcoidosis. Chest 1989; 96: 339-344.
8. Blaschke E, Eklund A, Hernbrand R. Determination of fibronectin and its degradation products in bronchoalveolar lavage fluid. Scand J Clin Lab Invest 1990; 50: 619-626.
9. Blaschke E, Eklund A, Hernbrand R. Extracellular matrix components in bronchoalveolar lavage fluid in sarcoidosis and their relationship to signs of alveolitis. Am Rev Respir Dis 1990; 141: 1020-1025.
10. Eklund AG, Sigurdardottir O, Öhrn M. Vitronectin and its relationship to other extracelullar matrix components in bronchoalveolar lavage fluid in sarcoidosis. Am Rev Respir Dis 1992; 145: 646-650.
11. Davidson JM. Biochemistry and turnover of lung interstitium. Eur Respir J 1990; 3: 1048-1068.
12. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972; 29 (Suppl. 124): 21-37.
13. Engström-Laurent A, Laurent UBG, Lilja K, Laurent T. Concentration of sodium hyaluronate in serum. Scand J Clin Lab Invest 1985; 45: 497-504.
14. Selmer J, Eriksen H, Clemmensen I. Native and degraded fibronectin: new immunological methods for distinction. Scand J Clin Lab Invest 1984; 44: 57-63.
15. Matthews DE, Farewell VT. Using and Understanding Medical Statistics, 2nd Edition. Basel, Switzerland: S. Karger AG, p. 178.
16. Dales LG, Friedman GD, Siegelaub AB, Seltzer CC. Cigarette smoking and serum chemistry tests. J Chron Dis 1974; 27: 293-307.
17. Gerrard JW, Heiner DC, Ko CG, Mink J, Meyers A, Dosman JA. Immunoglobulin levels in smokers and non-smokers. Ann Allergy 1980; 44: 261-262.
18. Andersen P, Pedersen DF, Bach B, Bonde GJ. Serum antibodies and immunoglobulins in smokers and non-smokers. Clin Exp Immunol 1982; 47: 467-473.
19. Bridges RB, Wyatt RJ, Rehm SR. Effect of smoking on peripheral blood leukocytes. Eur J Respir Dis 1985; 66 (Suppl. 139): 24-33.
20. Sköld CM, Hed J, Eklund A. Smoking cessation rapidly reduces cell recovery in bronchoalveolar lavage fluid, while alveolar macrophage fluorescence remains high. Chest 1992; 101: 989-995.
21. Stockley RA. Measurement of soluble proteins in lung secretions. Thorax 1984; 39: 241-247.
22. Reynolds HY. Bronchoalveolar lavage. Am Rev Respir Dis 1987; 135: 250-263.
23. Roberts CM, Cairns D, Bryant DH et al. Changes in epithelial lining fluid albumin associated with smoking and interstitial lung diseases. Eur Respir J 1993; 6: 110-115.
24. Daniele RP, Elias JA, Epstein PE, Rossman MD. Bronchoalveolar lavage: role in the pathogenesis, diagnosis and management of interstitial lung diseases. Ann Intern Med 1985; 102: 93-108.
25. Eklund A, Blaschke E. Relationship between changed alveolar-capillary permeability and angiotensin-converting enzyme activity in serum in sarcoidosis. Thorax 1986; 41: 629-634.
26. Jones KP, Edwards JH, Reynolds SP, Peters TJ, Davies BH. A comparison of albumin and urea as reference markers in bronchoalveolar lavage fluid from patients with interstitial lung diseases. Eur Respir J 1990; 3: 152-156.
27. Bjermer L, Eklund A, Blaschke E. Bronchoalveolar lavage fibronectin in patients with sarcoidosis: correlation to hyaluronan and disease activity. Eur Respir J 1992; 4: 965-971.
28. Brain JD. Macrophages in the respiratory tract. In: Fishman AP, Fisher AB, eds. Handbook of Physiology. The Respiratory System, Volume 1. Bethesda: American Physiological Society, 1985, pp. 447-471.
29. Sköld CM, Forslid J, Eklund A, Hed J. Metabolic activity in human alveolar macrophages increases after smoking cessation. Inflammation 1993; 17: 345-352.
30. Fraser JRE. Hyaluronan: Sources, turnover and metabolism. In: Lindh E, Thorell JI, eds. Clinical Impact of Bone and Connective Tissue Markers. London: Academic Press, 1989, pp. 31-49.
31. Bjermer L, Engström-Laurent A, Lundgren R, Rosenhall L, Hällgren R. Hyaluronic acid and procallagen III peptide in bronchoalveolar lavage fluid as indicators of lung disease in farmers lung. BMJ 1987; 295: 801-806.
32. Bjermer L, Engström-Laurent A, Thunell M, Hällgren R. Hyaluronic acid in bronchoalveolar lavage fluid in patients with sarcoidosis. The relationship to lavage mast cells. Thorax 1987; 42: 933-938.
33. Larsson K, Eklund A, Malmberg P, Bjermer L, Lundgren R, Belin L. Hyaluronic acid (Hyaluronan) in BAL-fluid distinguishes farmers with allergic alveolitis from farmers with asymptomatic alveolitis. Chest 1992; 101: 109-114.
34. Nettelbladt O, Bergh J, Schenholm M, Tengblad A, Hällgren R. Accumulation of hyaluronic acid in the alveolar-interstitial tissue in bleomycin-induced alveolitis. Am Rev Respir Dis 1989; 139: 759-762.
35. Nettelbladt O, Hällgren R. Hyaluronan (hyaluronic acid) in bronchoalveolar lavage fluid during the development of bleomycin-induced alveolitis in rats. Am Rev Respir Dis 1989; 140: 1028-1032.
36. Postlethwaite AE, Keski-Oja J, Balian G, Kang AH. Induction of fibroblast chemotaxis by fibronectin. J Exp Med 1981; 153: 494-499.
37. Rennard SI, Hunninghake GW, Bitterman PB, Crystal RG. Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts in sites of tissue injury in interstitial lung diseases. Proc Natl Acad Sci USA 1981; 78: 7147-7151.
38. Selmer J, Eriksen H, Clemmensen I. Native and degraded fibronectin: new immunological methods for distinction. Scand J Clin Lab Invest 1984; 44: 57-63.